Antineoplastic Agents: Hormones and Antagonists
OBICA1 “Pms-Bicalutamide tablet” 50 mg/tab
OCASO1 “Casodex tablet” 50 mg/tab
適應症：與LHRH類似藥品或手術去勢療法併用於進展性攝護腺癌。
Usual dose:
Metastatic carcinoma of the prostate (stage D2): 50 mg PO qd in conjunction with a luteinizing hormone-releasing hormone (LHRH) agonist.
Adverse effect:
Common: breast pain, gynecomastia, constipation, diarrhea, nausea, hot flashes, pulmonary and upper respiratory tract, weakness.
Serious: anemia, gastrointestinal or rectal bleeding, hepatotoxicity.
Related Entries
(Visited 14 times, 1 visits today)